Myeloma Canada will provide patient and caregiver input to the pan Canadian Oncology Drug Review (pCODR) process for myeloma treatment regimens that will be reviewed over the next few months. pCODR is the national agency that makes funding recommendations to provinces on oncology drugs approved for sale in Canada.
As always, your input is extremely important and, although there is no guarantee, it may help to improve the availability and access to important new myeloma drugs for patients across Canada.
The patient surveys should take about 15 minutes and the caregiver about 5 minutes. We ask that you complete the survey
Monday, October 1, 2018
.
If you have any questions about this survey, please write to
info@myeloma.ca
and include Patient or Caregiver Survey in the subject line.